Katharina S. Götze
A5066615327- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Histone Deacetylase Inhibitors Research
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Retinoids in leukemia and cellular processes
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- Hematological disorders and diagnostics
- Immune Cell Function and Interaction
- Bone and Joint Diseases
- Mesenchymal stem cell research
- Epigenetics and DNA Methylation
- Hemoglobinopathies and Related Disorders
- CAR-T cell therapy research
- Neutropenia and Cancer Infections
- Phagocytosis and Immune Regulation
- Lymphoma Diagnosis and Treatment
- Chemokine receptors and signaling
- Sarcoma Diagnosis and Treatment
- Immune cells in cancer
- Platelet Disorders and Treatments
Technical University of Munich
2016-2025
German Cancer Research Center
2016-2025
Deutschen Konsortium für Translationale Krebsforschung
2016-2025
Ludwig-Maximilians-Universität München
2010-2025
Klinikum rechts der Isar
2015-2024
Heidelberg University
2014-2024
Johannes Gutenberg University Mainz
2024
München Klinik
2013-2021
German Marine Research Consortium
2018-2021
European Molecular Biology Laboratory
2021
Purpose To analyze the frequency and prognostic impact of isocitrate dehydrogenase 1 (IDH1) 2 (IDH2) mutations in acute myeloid leukemia (AML). Patients Methods We studied 805 adults (age range, 16 to 60 years) with AML enrolled on German-Austrian Study Group (AMLSG) treatment trials HD98A APL HD95 for exon 4 IDH1 IDH2. were also NPM1, FLT3, MLL, CEBPA mutations. The median follow-up survival was 6.3 years. Results IDH found 129 patients (16.0%) —IDH1 61 (7.6%), IDH2 70 (8.7%). Two had both...
Kinase inhibitors are important cancer therapeutics. Polypharmacology is commonly observed, requiring thorough target deconvolution to understand drug mechanism of action. Using chemical proteomics, we analyzed the spectrum 243 clinically evaluated kinase drugs. The data revealed previously unknown targets for established drugs, offered a perspective on "druggable" kinome, highlighted (non)kinase off-targets, and suggested potential therapeutic applications. Integration phosphoproteomic...
Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2 SMAD3 signaling, showed promising results phase 2 study.In double-blind, placebo-controlled, 3 trial, we randomly assigned patients very-low-risk, low-risk, or intermediate-risk (defined according...
The tet oncogene family member 2 (TET2) gene was recently identified to be mutated in myeloid disorders including acute leukemia (AML). To date, there is increasing evidence for a functional role of TET2 mutations (TET2(mut)) AML. Thus, we explored the frequency, gene-expression pattern, and clinical impact TET2(mut) large cohort patients with AML context other AML-associated aberrations.Samples from 783 younger adult were analyzed presence (coding exons 3 11), results correlated data...
PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene ( FLT3-ITD) have a poor prognosis, frequently relapse, and die as result of AML. It is currently unknown whether maintenance therapy using FLT3 inhibitors, such multitargeted inhibitor sorafenib, improves outcome after HCT. PATIENTS AND METHODS In randomized, placebo-controlled, double-blind...
Purpose To assess the impact of allogeneic hematopoietic stem-cell transplantation (HSCT) from matched related donors (MRDs) and unrelated (MUDs) on outcome in high-risk patients with acute myeloid leukemia (AML) within a prospective multicenter treatment trial. Patients Methods Between 1998 2004, 844 (median age, 48 years; range, 16 to 62 years) AML were enrolled onto protocol AMLHD98A that included risk-adapted strategy. High risk was defined by presence unfavorable cytogenetics and/or no...
In a previous randomized trial, AML HD98B, we showed that administration of all-trans retinoic acid in addition to intensive chemotherapy improved the outcome older patients with acute myeloid leukemia. The objectives this study were evaluate prognostic impact gene mutations and identify predictive genetic factors for treatment effect.Data from mutation analyses NPM1, CEBPA, FLT3, MLL genes correlated 61 years treated within HD98B trial.The frequencies were: 23%; 8.5% (analysis restricted...
Purpose The tet oncogene family member 2 (TET2) gene was recently identified to be mutated in myeloid disorders including acute leukemia (AML). To date, there is increasing evidence for a functional role of TET2 mutations (TET2 mut ) AML. Thus, we explored the frequency, gene-expression pattern, and clinical impact large cohort patients with AML context other AML-associated aberrations. Patients Methods Samples from 783 younger adult were analyzed presence (coding exons 3 11), results...
Erythropoiesis-stimulating agents are first choice for treating anemia in low-risk MDS. This double-blind, placebo-controlled study assessed the efficacy and safety of epoetin-α IPSS low- or intermediate-1 risk (i.e., low-risk) MDS patients with Hb ≤ 10.0 g/dL, no moderate RBC transfusion dependence (≤4 units/8 weeks). Patients were randomized, 2:1, to receive 450 IU/kg/week placebo 24 weeks, followed by treatment extension responders. The primary endpoint was erythroid response (ER) through...
We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry. Adult with newly diagnosed AML at 63 centers in Germany Austria were followed within the AMLSG BiO registry (NCT01252485). Between January 1, 2012, December 31, 2014, data 3525 (45% women) collected. The median was 65 years (range 18-94). comparison age-specific incidence rates epidemiological cancer registries revealed excellent coverage < 70...
Background— The immune system orchestrates the repair of infarcted myocardium. Imaging cellular inflammatory response by 18 F-fluorodeoxyglucose ( F-FDG) positron emission tomography/magnetic resonance imaging in heart has been demonstrated preclinical and clinical studies. However, relevance post-MI F-FDG uptake not elucidated. objective this study was to explore value patients after acute myocardial infarction as a biosignal for left ventricular functional outcome. Methods Results— We...